Decreased Neurokinin-1 (Substance P) Receptor Binding in Patients with Panic Disorder: Positron Emission Tomographic Study with [18F]SPA-RQ

Biological Psychiatry

Volumn 66, Issue 1, 2009, Pages 94-97

  Fujimura, Yota ^a   Yasuno, Fumihiko ^a   Farris, Amanda ^a   Liow, Jeih San ^a   Geraci, Marilla ^a   Drevets, Wayne ^a   Pine, Daniel S ^a   Ghose, Subroto ^b   Lerner, Alicja ^a   Hargreaves, Richard ^c   Burns, H Donald ^c   Morse, Cheryl ^a   Pike, Victor W ^a   Innis, Robert B ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

NK1 receptor; panic attack; panic disorder; positron emission tomography (PET); substance P

Indexed keywords

DOXAPRAM; NEUROKININ 1 RECEPTOR; RADIOPHARMACEUTICAL AGENT; SPA RQ F 18; SUBSTANCE P; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG UPTAKE; FEMALE; HUMAN; MALE; PANIC; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN SYNTHESIS; RECEPTOR BINDING; RECURRENT DISEASE;

ADULT; BRAIN; BRAIN MAPPING; FEMALE; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTORS, NEUROKININ-1; TETRAZOLES;

EID: 67349222818     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.12.027     Document Type: Article

References (19)

1. Carrasco G.A., and Van de Kar L.D. Neuroendocrine pharmacology of stress. Eur J Pharmacol 463 (2003) 235-272
2. Michelgard A., Appel L., Pissiota A., Frans O., Langstrom B., Bergstrom M., et al. Symptom provocation in specific phobia affects the substance P neurokinin-1 receptor system. Biol Psychiatry 61 (2007) 1002-1006
3. 18F]SPA-RQ). Mol Imaging Biol 6 (2004) 373-384
4. Abelson J.L., Nesse R.M., Weg J.G., and Curtis G.C. Respiratory psychophysiology and anxiety: Cognitive intervention in the doxapram model of panic. Psychosom Med 58 (1996) 302-313
5. Shear M.K., Rucci P., Williams J., Frank E., Grochocinski V., Vander Bilt J., et al. Reliability and validity of the Panic Disorder Severity Scale: Replication and extension. J Psychiatr Res 35 (2001) 293-296
6. 1 receptors with PET. J Labelled Comp Radiopharm 49 (2006) 17-31
7. Yasuno F., Hasnine A.H., Suhara T., Ichimiya T., Sudo Y., Inoue M., et al. Template-based method for multiple volumes of interest of human brain PET images. Neuroimage 16 (2002) 577-586
8. Innis R.B., Cunningham V.J., Delforge J., Fujita M., Gjedde A., Gunn R.N., et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27 (2007) 1533-1539
9. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23 (2003) 1096-1112
10. 18F]SPA-RQ in human subjects: Assessment of reference tissue models and their test-retest reproducibility. Synapse 61 (2007) 242-251
11. Koszycki D., Bradwejn J., and Bourin M. Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers. Eur Neuropsychopharmacol 1 (1991) 137-141
12. Beck A.T., Epstein N., Brown G., and Steer R.A. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol 56 (1988) 893-897
13. 1) receptors in the human brain. Mol Imaging Biol 7 (2005) 262-272
14. Furmark T., Appel L., Michelgard A., Wahlstedt K., Ahs F., Zancan S., et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58 (2005) 132-142
15. Kramer M.S., Cutler N., Feighner J., Shrivastava R., Carman J., Sramek J.J., et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281 (1998) 1640-1645
16. Keller M., Montgomery S., Ball W., Morrison M., Snavely D., Liu G., et al. Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 59 (2006) 216-223
17. 1 receptor internalisation in the basolateral amygdala. Brain Res 848 (1999) 90-95
18. Ebner K., Singewald G.M., Whittle N., Ferraguti F., and Singewald N. Neurokinin 1 receptor antagonism promotes active stress coping via enhanced septal 5-HT transmission. Neuropsychopharmacology 33 (2008) 1929-1941
19. Geracioti Jr. T.D., Carpenter L.L., Owens M.J., Baker D.G., Ekhator N.N., Horn P.S., et al. Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry 163 (2006) 637-643